Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Inflammatory Myofibroblastic Tumor”

15 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 15 results

Early research (Phase 1)Study completedNCT01742286
What this trial is testing

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
ALK-activated Tumors
Novartis Pharmaceuticals 83
Testing effectiveness (Phase 2)Ended earlyNCT02465528
What this trial is testing

Ceritinib Rare Indications Study in ALK+ Tumors

Who this might be right for
Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more
Novartis Pharmaceuticals 22
Not applicableUnknownNCT04572594
What this trial is testing

Molecular Profiling and Molecular Labeling of Inflammatory Myofibroblastic Tumor

Who this might be right for
Inflammatory Myofibroblatic Tumor
Sun Yat-sen University 29
Not applicableNo Longer AvailableNCT05100134
What this trial is testing

Managed Access Programs for LDK378, Ceritinib

Who this might be right for
Anaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT04925609
What this trial is testing

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveInflammatory Myofibroblastic TumorOther Solid Tumor
Princess Maxima Center for Pediatric Oncology 65
Not applicableNo Longer AvailableNCT03085186
What this trial is testing

Treatment With Crizotinib Single Patient Expanded Access IND 134375

Who this might be right for
Inflammatory Myofibroblastic Tumour
Jean M. Tersak, M.D.
Large-scale testing (Phase 3)Active Not RecruitingNCT02180867
What this trial is testing

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Who this might be right for
Alveolar Soft Part SarcomaAngiomatoid Fibrous HistiocytomaAtypical Fibroxanthoma+33 more
National Cancer Institute (NCI) 140
Testing effectiveness (Phase 2)Looking for participantsNCT06239272
What this trial is testing

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Who this might be right for
Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+6 more
St. Jude Children's Research Hospital 139
Post-approval studies (Phase 4)Active Not RecruitingNCT05160922
What this trial is testing

Crizotinib Continuation Clinical Study

Who this might be right for
NSCLCALCLIMT
Pfizer 27
Large-scale testing (Phase 3)UnknownNCT03874273
What this trial is testing

Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

Who this might be right for
Inflammatory Myofibroblastic Tumor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 25
Testing effectiveness (Phase 2)Looking for participantsNCT04094610
What this trial is testing

Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid TumorsLymphoma+1 more
Turning Point Therapeutics, Inc. 75
Testing effectiveness (Phase 2)WithdrawnNCT04260009
What this trial is testing

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Who this might be right for
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell LymphomaInflammatory Myofibroblastic TumorsSolid Tumors
Takeda
Testing effectiveness (Phase 2)Study completedNCT01625234
What this trial is testing

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Who this might be right for
Advanced Solid TumorsNon-small Cell Lung Cancer
Xcovery Holdings, Inc. 131
Not applicableStudy completedNCT02971176
What this trial is testing

Low-dose Protocol for Computed Tomography-guided Lung Biopsy

Who this might be right for
Lung Cancer, AdenocarcinomaLung Inflammatory Pseudotumor
Xuzhou Central Hospital 280
Testing effectiveness (Phase 2)Study completedNCT01524926
What this trial is testing

CREATE: Cross-tumoral Phase 2 With Crizotinib

Who this might be right for
Locally Advanced and/or Metastatic Anaplastic Large Cell LymphomaLocally Advanced and/or Metastatic Inflammatory Myofibroblastic TumorLocally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1+3 more
European Organisation for Research and Treatment of Cancer - EORTC 582